Study of BL-M24D1 for multiple myeloma and other blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma or another blood cancer that has not improved with standard treatments or for which no standard treatment exists.
- You must be at least 18 years old and for phase Ia, up to 75 years old.
- You need to be in fairly good health (able to do daily activities, ECOG score 0 or 1).
- Your heart, liver, kidney, and blood clotting functions must be working well enough as checked by tests.
- You cannot be pregnant or breastfeeding, and you must use effective birth control during the study and for 6 months after.
- You cannot have certain other serious medical conditions, like severe heart disease, active infections, or other cancers within the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests a new drug, BL-M24D1, in people with advanced or metastatic digestive tract cancers or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new antibody-based drug called BL-M11D1 in patients whose myelodysplastic syndrome (a blood disorder where the bone marrow doesn't make healthy blood cells) has come back or stopped responding to previous treatments. The drug targets CD33, a protein on certain blood cells, to help the immune system fight the disease.
This trial tests a new drug called BL-M08D1 for people with lymphoma or other blood cancers that came back or didn't respond to standard treatments. It aims to see if the drug can help when other options are no longer working.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.